Evidence map›Paper›PMID 27365110›Full record

ArticleLasers in medical science2016

Effects of combination of melatonin and laser irradiation on ovarian cancer cells and endothelial lineage viability.

Maryam Akbarzadeh, Mohammad Nouri, Maryam Vahidi Banekohal, Omid Cheraghi, Habib Tajalli, Aliakbar Movassaghpour, Sina Soltani, Hadi Cheraghi, Navid Feizy, Soheila Montazersaheb and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Lasers in medical science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Melatonin: An Anti-Tumor Agent in Hormone-Dependent Cancers.International journal of endocrinology · 2018
    Review
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Maryam AkbarzadehStem Cell Research Center, Tabriz University of Medical Sciences, Imam Reza St., Golgasht St., 5166614756, Tabriz, Iran.
Mohammad NouriStem Cell Research Center, Tabriz University of Medical Sciences, Imam Reza St., Golgasht St., 5166614756, Tabriz, Iran.
Maryam Vahidi BanekohalStem Cell Research Center, Tabriz University of Medical Sciences, Imam Reza St., Golgasht St., 5166614756, Tabriz, Iran.
Omid CheraghiStem Cell Research Center, Tabriz University of Medical Sciences, Imam Reza St., Golgasht St., 5166614756, Tabriz, Iran.
Habib TajalliResearch Institute for Applied Physics and Astronomy, University of Tabriz, Tabriz, Iran.
Aliakbar MovassaghpourHematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Sina SoltaniStem Cell Research Center, Tabriz University of Medical Sciences, Imam Reza St., Golgasht St., 5166614756, Tabriz, Iran.
Hadi CheraghiDepartment of Clinical Pathology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
Navid FeizyStem Cell Research Center, Tabriz University of Medical Sciences, Imam Reza St., Golgasht St., 5166614756, Tabriz, Iran.
Soheila MontazersahebStem Cell Research Center, Tabriz University of Medical Sciences, Imam Reza St., Golgasht St., 5166614756, Tabriz, Iran.
Reza RahbarghaziStem Cell Research Center, Tabriz University of Medical Sciences, Imam Reza St., Golgasht St., 5166614756, Tabriz, Iran. Rezarahbardvm@gmail.com.
Nasser SamadiStem Cell Research Center, Tabriz University of Medical Sciences, Imam Reza St., Golgasht St., 5166614756, Tabriz, Iran. drnsamadi@yahoo.com.
Imam Reza Hospital · IRTabriz University of Medical Sciences · IRUniversity of Tabriz · IRUniversity of Tehran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main goal of anti-cancer therapeutic approaches is to induce apoptosis in tumor masses but not in the normal tissues. Nevertheless, the combination of photodynamic irradiation with complementary oncostatic agents contributes to better therapeutic performance. Here, we applied two different cell lines; SKOV3 ovarian carcinoma cells and HUVECs umbilical cord cells as in vitro models to pinpoint whether pharmacological concentration of melatonin in combination with photodynamic therapy induces cell cytotoxicity. The cells were separately treated with various concentrations of melatonin (0 to 10 mM) and photodynamic irradiation alone or in combination. Cells were preliminary exposed to increasing concentrations of melatonin for 24 h and subsequently underwent laser irradiation for 60 s with an output power of 80 mW in continuous mode at 675 nm wavelength and a total light dose of 13.22 J/cm

Indexed as

ApoptosisCell Line, TumorCell SurvivalFemaleHSP70 Heat-Shock ProteinsHumansHuman Umbilical Vein Endothelial CellsMelatoninOvarian NeoplasmsPhotochemotherapyPhotosensitizing AgentsReactive Oxygen SpeciesHSP70 Heat-Shock ProteinsMelatoninPhotosensitizing AgentsReactive Oxygen SpeciesHeat shock protein 70HUVECsLaser irradiationMelatoninSKOV3

Identifiers

PMID27365110
OpenAlexW2469661049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.